Citius Pharmaceuticals In... (CTXR)
The price, the headline numbers and the latest news, in one place.
Citius Pharmaceuticals Inc. (CTXR) Stock Price, Analysis & Data
No data available
| Bid | 0.44 |
| Market Cap | 16.53M |
| Revenue (ttm) | 7.11M |
| Net Income (ttm) | -46.27M |
| 0.99 | |
| -1.67 | |
| n/a | |
| -0.42 | |
| P/B (ttm) | 0.25 |
| P/S (ttm) | 2.33 |
| Earnings Date | Dec 29, 2026 |
| Ask | 0.78 |
| Volume | 361,731 |
| Avg. Volume (20D) | 561,298 |
| Open | 0.61 |
| Previous Close | 0.61 |
| Day's Range | 0.59 - 0.63 |
| 52-Week Range | 0.47 - 2.19 |
| Analyst | Strong Buy |
| Price Target | 4 (566.67%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CTXR
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulatio...
Financial Performance
In 2025, Citius Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -37.43M, a decrease of -4.36%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for CTXR stock is "Strong Buy". The 12-month stock price forecast is 4, which is upside of 566.67% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $1.67M misses estimates by $0, with Infinity% YoY growth.
- EPS of -0.34 exceeds estimates by 0.02, with 57.50% YoY growth.
Analysts project revenue of ... Upgrade
